{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:04:45Z","timestamp":1790823885637,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T00:00:00Z","timestamp":1272326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/nrneph.2010.54","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T10:02:05Z","timestamp":1272362525000},"page":"352-360","source":"Crossref","is-referenced-by-count":118,"title":["RAGE and the pathogenesis of chronic kidney disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Vivette","family":"D'Agati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,27]]},"reference":[{"key":"BFnrneph201054_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/07853890902806576","volume":"41","author":"SF Yan","year":"2009","unstructured":"Yan, S. F., Du Yan, S., Ramasamy, R. & Schmidt, A. M. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann. Med. 41, 408\u2013422 (2009).","journal-title":"Ann. Med."},{"key":"BFnrneph201054_CR2","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1089\/ars.2009.2484","volume":"11","author":"A Negre-Salvayre","year":"2009","unstructured":"Negre-Salvayre, A., Salvayre, R., Auge, N., Pamplona, R. & Portero-Ot\u00edn, M. Hyperglycemia and glycation in diabetic complications. Antioxid. Redox Signal. 11, 3071\u20133109 (2009).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph201054_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/ki.2009.401","volume":"114","author":"H Vlassara","year":"2009","unstructured":"Vlassara, H. et al. Role of oxidants\/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int. Suppl. 114, S3\u2013S11 (2009).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph201054_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1172\/JCI3042","volume":"104","author":"MM Anderson","year":"1999","unstructured":"Anderson, M. M., Requena, J. R., Crowley, J. R., Thorpe, S. R. & Heinecke, J. W. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 104, 103\u2013113 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201054_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/CIRCRESAHA.107.165308","volume":"102","author":"JS Chang","year":"2008","unstructured":"Chang, J. S. et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res. 102, 905\u2013913 (2008).","journal-title":"Circ. Res."},{"key":"BFnrneph201054_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1189\/jlb.0409230","volume":"86","author":"R Ramasamy","year":"2009","unstructured":"Ramasamy, R., Yan, S. F. & Schmidt, A. M. RAGE: therapeutic target and biomarker of the inflammatory response: the evidence mounts. J. Leukoc. Biol. 86, 505\u2013512 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrneph201054_CR7","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1089\/ars.2007.1999","volume":"10","author":"ZJ Guo","year":"2008","unstructured":"Guo, Z. J. et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid. Redox Signal. 10, 1699\u20131712 (2008).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph201054_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0891-5849(90)90112-V","volume":"9","author":"K Asayama","year":"1990","unstructured":"Asayama, K. et al. Antioxidant enzymes and lipoperoxides in blood in uremic children and adolescents. Free Radic. Biol. Med. 9, 105\u2013109 (1990).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnrneph201054_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1538\/expanim.57.423","volume":"57","author":"Y Hirasawa","year":"2008","unstructured":"Hirasawa, Y. et al. Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reactions. Exp. Anim. 57, 423\u2013432 (2008).","journal-title":"Exp. Anim."},{"key":"BFnrneph201054_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1681\/ASN.2007101109","volume":"19","author":"J Guo","year":"2008","unstructured":"Guo, J. et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol. 19, 961\u2013972 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR11","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1681\/ASN.V1191656","volume":"11","author":"N Tanji","year":"2000","unstructured":"Tanji, N. et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11, 1656\u20131666 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2215\/CJN.04291007","volume":"3","author":"E Linden","year":"2008","unstructured":"Linden, E. et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end product (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin. J. Am. Soc. Nephrol. 3, 691\u2013698 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/00365510510013794","volume":"65","author":"N Matsunaga","year":"2005","unstructured":"Matsunaga, N. et al. Advanced glycation end product is implicated in amyloid-related kidney complications. Scand. J. Clin. Lab. Invest. 65, 263\u2013271 (2005).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"BFnrneph201054_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1172\/JCI11771","volume":"108","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto, Y. et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 108, 261\u2013268 (2001).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201054_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0002-9440(10)63909-0","volume":"162","author":"TM Wendt","year":"2003","unstructured":"Wendt, T. M. et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123\u20131137 (2003).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph201054_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2337\/diabetes.53.1.166","volume":"53","author":"A Flyvbjerg","year":"2004","unstructured":"Flyvbjerg, A. et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53, 166\u2013172 (2004).","journal-title":"Diabetes"},{"key":"BFnrneph201054_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1677\/joe.1.06524","volume":"188","author":"LJ Jensen","year":"2006","unstructured":"Jensen, L. J. et al. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. 188, 493\u2013501 (2006).","journal-title":"J. Endocrinol."},{"key":"BFnrneph201054_CR18","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.2337\/db06-0221","volume":"55","author":"KM Myint","year":"2006","unstructured":"Myint, K. M. et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55, 2510\u20132522 (2006).","journal-title":"Diabetes"},{"key":"BFnrneph201054_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/diabetes.55.02.06.db05-0702","volume":"55","author":"R Inagi","year":"2006","unstructured":"Inagi, R. et al. A severe diabetic nephropathy model with early development of nodule-like lesions by megsin overexpression in RAGE\/iNOS transgenic mice. Diabetes 55, 356\u2013366 (2006).","journal-title":"Diabetes"},{"key":"BFnrneph201054_CR20","unstructured":"States AOE-SRDITU: US Renal Data System: USRDS 2002 Annual Data Report (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD, USA, 2002)."},{"key":"BFnrneph201054_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jacc.2008.10.008","volume":"53","author":"JS Skyler","year":"2009","unstructured":"Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. J. Am. Coll. Cardiol. 53, 298\u2013304 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph201054_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer, M. et al. Renal and retinal effects of enalopril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40\u201351 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201054_CR23","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI119853","volume":"100","author":"K Horie","year":"1997","unstructured":"Horie, K. et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J. Clin. Invest. 100, 2995\u20133004 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201054_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1100\/tsw.2009.133","volume":"9","author":"E Stitt-Cavanagh","year":"2009","unstructured":"Stitt-Cavanagh, E., MacLeod, L. & Kennedy, C. The podocyte in diabetic kidney disease. ScientificWorldJournal 9, 1127\u20131139 (2009).","journal-title":"ScientificWorldJournal"},{"key":"BFnrneph201054_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1053\/j.ajkd.2006.02.182","volume":"47","author":"S Basi","year":"2006","unstructured":"Basi, S. & Lewis, J. B. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am. J. Kidney Dis. 47, 927\u2013946 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201054_CR26","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1038\/sj.ki.5002384","volume":"106","author":"JJ Li","year":"2007","unstructured":"Li, J. J. et al. Podocyte biology in diabetic nephropathy. Kidney Int. Suppl. 106, S36\u2013S42 (2007).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph201054_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.mvr.2005.10.001","volume":"70","author":"L Pala","year":"2005","unstructured":"Pala, L. et al. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: biological effects and advanced glycosilation end products modulation. Microvasc. Res. 70, 179\u2013188 (2005).","journal-title":"Microvasc. Res."},{"key":"BFnrneph201054_CR28","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1681\/ASN.2009070721","volume":"20","author":"FC Brosius 3rd","year":"2009","unstructured":"Brosius, F. C. 3rd et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2503\u20132512 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1681\/ASN.2006050459","volume":"18","author":"T Nakagawa","year":"2007","unstructured":"Nakagawa, T. et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18, 539\u2013550 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR30","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2353\/ajpath.2009.080605","volume":"174","author":"T Kosugi","year":"2009","unstructured":"Kosugi, T. et al. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitital injury, in diabetic eNOS knockout mice. Am. J. Pathol. 174, 1221\u20131229 (2009).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph201054_CR31","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.2337\/diabetes.53.12.3248","volume":"53","author":"S Zheng","year":"2004","unstructured":"Zheng, S. et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53, 3248\u20133257 (2004).","journal-title":"Diabetes"},{"key":"BFnrneph201054_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ar.20625","volume":"291","author":"JM Teiken","year":"2008","unstructured":"Teiken, J. M., Audettey, J. L., Laturnus, D. I., Zheng, S., Epstein, P. N. & Carlson, E. C. Podocyte loss in aging OVE26 diabetic mice. Anat. Rec. (Hoboken) 291, 114\u2013121 (2008).","journal-title":"Anat. Rec. (Hoboken)"},{"key":"BFnrneph201054_CR33","doi-asserted-by":"crossref","unstructured":"Reiniger, N. et al. Deletion of the receptor for advanced glycation endproducts preserves renal function in the diabetic OVE26 mouse. Abstract, Annual Meeting American Society of Nephrology SA-PO2913 (2009).","DOI":"10.2337\/db09-1766"},{"key":"BFnrneph201054_CR34","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1046\/j.1523-1755.2000.00342.x","volume":"58","author":"Y Wang","year":"2000","unstructured":"Wang, Y., Wang, Y. P., Tay, Y. C. & Harris, D. C. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 58, 1797\u20131804 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph201054_CR35","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1681\/ASN.2004121084","volume":"16","author":"M Koshikawa","year":"2005","unstructured":"Koshikawa, M. et al. Role of p38 mitogen activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J. Am. Soc. Nephrol. 16, 2690\u20132701 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/10715760802657308","volume":"43","author":"L Yang","year":"2009","unstructured":"Yang, L., Zheng, S. & Epstein, P. N. Metallothionein over-expression in podocytes reduces adriamycin nephropathy. Free Radic. Res. 43, 174\u2013182 (2009).","journal-title":"Free Radic. Res."},{"key":"BFnrneph201054_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/ndt\/gfi210","volume":"21","author":"L Gu","year":"2006","unstructured":"Gu, L. et al. Role of receptor for advanced glycation end-products and signaling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 21, 299\u2013313 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201054_CR38","doi-asserted-by":"publisher","first-page":"F85","DOI":"10.1152\/ajprenal.90642.2008","volume":"297","author":"EY Lee","year":"2009","unstructured":"Lee, E. Y. et al. The monocyte chemoattractant protein-1\/CCR2 loop, inducible by TGF-beta, increased podocyte motility and albumin permeability. Am. J. Physiol. Renal Physiol. 297, F85\u2013F94 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201054_CR39","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/sj.ki.5002456","volume":"72","author":"PY Chuang","year":"2007","unstructured":"Chuang, P. Y., Yu, Q., Fang, W., Uribarri, J. & He, J. C. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 72, 965\u2013976 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph201054_CR40","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1681\/ASN.2008050514","volume":"20","author":"MT Coughlan","year":"2009","unstructured":"Coughlan, M. T. et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 20, 742\u2013752 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1159\/000191467","volume":"29","author":"C R\u00fcster","year":"2009","unstructured":"R\u00fcster, C. et al. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am. J. Nephrol. 29, 538\u2013550 (2009).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201054_CR42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1006\/bbrc.1998.8489","volume":"245","author":"H Tsuji","year":"1998","unstructured":"Tsuji, H. et al. Ribozyme targeting of receptor for advanced glycation endproducts in mouse mesangial cells. Biochem. Biophys. Res. Commun. 245, 583\u2013588 (1998).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneph201054_CR43","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI11951","volume":"108","author":"MD Oldfield","year":"2001","unstructured":"Oldfield, M. D. et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 108, 1853\u20131863 (2001).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201054_CR44","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/01.ASN.0000131526.99506.F7","volume":"15","author":"FF Hou","year":"2004","unstructured":"Hou, F. F. et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J. Am. Soc. Nephrol. 15, 1889\u20131896 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"SD Yan","year":"1996","unstructured":"Yan, S. D. et al. RAGE and amyloid beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685\u2013691 (1996).","journal-title":"Nature"},{"key":"BFnrneph201054_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/76216","volume":"6","author":"SD Yan","year":"2000","unstructured":"Yan, S. D. et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643\u2013651 (2000).","journal-title":"Nat. Med."},{"key":"BFnrneph201054_CR47","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2337\/db07-0326","volume":"57","author":"LG Bucciarelli","year":"2008","unstructured":"Bucciarelli, L. G. et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57, 1941\u20131951 (2008).","journal-title":"Diabetes"},{"key":"BFnrneph201054_CR48","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/CIRCULATIONAHA.105.575993","volume":"113","author":"LG Bucciarelli","year":"2006","unstructured":"Bucciarelli, L. G. et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113, 1226\u20131234 (2006).","journal-title":"Circulation"},{"key":"BFnrneph201054_CR49","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jhep.2008.11.022","volume":"50","author":"S Zeng","year":"2009","unstructured":"Zeng, S. et al. Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia\/reperfusion injury. J. Hepatol. 50, 929\u2013936 (2009).","journal-title":"J. Hepatol."},{"key":"BFnrneph201054_CR50","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jtcvs.2008.05.032","volume":"136","author":"DI Sternberg","year":"2008","unstructured":"Sternberg, D. I. et al. Blockade of receptor for advanced glycation endproduct attenuates pulmonary reperfusion injury in mice. J. Thorac. Cardiovasc. Surg. 136, 1576\u20131585 (2008).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"BFnrneph201054_CR51","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jocn.2007.12.011","volume":"16","author":"BG Hassid","year":"2009","unstructured":"Hassid, B. G. et al. Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia. J. Clin. Neurosci. 16, 302\u2013306 (2009).","journal-title":"J. Clin. Neurosci."},{"key":"BFnrneph201054_CR52","doi-asserted-by":"publisher","first-page":"12023","DOI":"10.1523\/JNEUROSCI.2435-08.2008","volume":"28","author":"S Muhammad","year":"2008","unstructured":"Muhammad, S. et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28, 12023\u201312031 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrneph201054_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/MNH.0b013e3280403c4e","volume":"16","author":"CY Lu","year":"2007","unstructured":"Lu, C. Y., Hartono, J., Senitko, M. & Chen, J. The inflammatory response to ischemic acute kidney injury: a result of the 'right stuff' in the 'wrong place'? Curr. Opin. Nephrol. Hypertens. 16, 83\u201389 (2007).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph201054_CR54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bbagrm.2009.11.012","volume":"1799","author":"H Rauvala","year":"2010","unstructured":"Rauvala, H. & Rouhianen, A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim. Biophys. Acta 1799, 164\u2013170 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneph201054_CR55","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1172\/JCI22832","volume":"115","author":"JC Leemans","year":"2005","unstructured":"Leemans, J. C. et al. Renal-associated TLR2 mediates ischemia\/reperfusion injury in the kidney. J. Clin. Invest. 115, 2894\u20132903 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201054_CR56","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.4049\/jimmunol.178.10.6252","volume":"178","author":"AA Shigeoka","year":"2007","unstructured":"Shigeoka, A. A. et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J. Immunol. 178, 6252\u20136258 (2007).","journal-title":"J. Immunol."},{"key":"BFnrneph201054_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3747\/pdi.2009.00031","volume":"30","author":"S M\u00fcller-Krebs","year":"2010","unstructured":"M\u00fcller-Krebs, S. et al. Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure. Perit. Dial. Int. 30, 35\u201340 (2010).","journal-title":"Perit. Dial. Int."},{"key":"BFnrneph201054_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-2004-817822","volume":"112","author":"G Rudofsky Jr","year":"2004","unstructured":"Rudofsky, G. Jr et al. A 63bp deletion in the promoter of RAGE correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 112, 135\u2013141 (2004).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"BFnrneph201054_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1262-3636(07)70164-7","volume":"31","author":"G Prevost","year":"2005","unstructured":"Prevost, G. et al. Polymorphisms of the receptor for advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab. 31, 35\u201339 (2005).","journal-title":"Diabetes Metab."},{"key":"BFnrneph201054_CR60","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-006-0412-3","volume":"49","author":"E Lindholm","year":"2006","unstructured":"Lindholm, E. et al. The -374 T\/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic subjects. Diabetologia 49, 2745\u20132755 (2006).","journal-title":"Diabetologia"},{"key":"BFnrneph201054_CR61","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/ndt\/gfh711","volume":"20","author":"K Kankov\u00e1","year":"2005","unstructured":"Kankov\u00e1, K., Stejskalov\u00e1, A., Hertlov\u00e1, M. & Znojil, V. Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. Nephrol. Dial. Transplant. 20, 1093\u20131102 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201054_CR62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinbiochem.2008.12.006","volume":"42","author":"M Kalousov\u00e1","year":"2009","unstructured":"Kalousov\u00e1, M. et al. RAGE polymorphisms, renal function, and histological finding at 12 months after renal transplantation. Clin. Biochem. 42, 347\u2013352 (2009).","journal-title":"Clin. Biochem."},{"key":"BFnrneph201054_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/sj.gene.6363861","volume":"3","author":"MA Hofmann","year":"2002","unstructured":"Hofmann, M. A. et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3, 123\u2013135 (2002).","journal-title":"Genes Immun."},{"key":"BFnrneph201054_CR64","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.bbagen.2007.07.003","volume":"1770","author":"M Osawa","year":"2007","unstructured":"Osawa, M. et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim. Biophys. Acta 1770, 1468\u20131474 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneph201054_CR65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ng.500","volume":"42","author":"DB Hancock","year":"2010","unstructured":"Hancock, D. B. et al. Meta-analysis of genome wide association studies identify multiple loci associated with pulmonary function. Nat. Genet. 42, 42\u201352 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrneph201054_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/ng.501","volume":"42","author":"E Repapi","year":"2010","unstructured":"Repapi, E. et al. Genome wide association study identifies five loci associated with lung function. Nat. Genet. 42, 36\u201344 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrneph201054_CR67","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1254\/jphs.CPJ04005X","volume":"97","author":"H Yonekura","year":"2005","unstructured":"Yonekura, H., Yamamoto, Y., Sakurai, S., Watanabe, T. & Yamamoto, H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci. 97, 305\u2013311 (2005).","journal-title":"J. Pharmacol. Sci."},{"key":"BFnrneph201054_CR68","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1096\/fj.07-9909com","volume":"22","author":"BI Hudson","year":"2008","unstructured":"Hudson, B. I. et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22, 1572\u20131580 (2008).","journal-title":"FASEB J."},{"key":"BFnrneph201054_CR69","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22, 3716\u20133727 (2008).","journal-title":"FASEB J."},{"key":"BFnrneph201054_CR70","doi-asserted-by":"publisher","first-page":"35507","DOI":"10.1074\/jbc.M806948200","volume":"283","author":"L Zhang","year":"2008","unstructured":"Zhang, L. et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 283, 35507\u201335516 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph201054_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2840-6-9","volume":"6","author":"PM Humpert","year":"2007","unstructured":"Humpert, P. M. et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 6, 9 (2007).","journal-title":"Cardiovasc. Diabetol."},{"key":"BFnrneph201054_CR72","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.diabet.2008.04.003","volume":"34","author":"N Grossin","year":"2008","unstructured":"Grossin, N. et al. Severity of diabetic microvascular complications is associated with low soluble RAGE level. Diabetes Metab. 34, 392\u2013395 (2008).","journal-title":"Diabetes Metab."},{"key":"BFnrneph201054_CR73","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.diabres.2008.04.013","volume":"81","author":"T Gohda","year":"2008","unstructured":"Gohda, T. et al. Increased serum endogenous secretory receptor for advanced glycation endproducts (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res. Clin. Pract. 81, 196\u2013201 (2008).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"BFnrneph201054_CR74","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.ajkd.2005.12.028","volume":"47","author":"M Kalousov\u00e1","year":"2006","unstructured":"Kalousov\u00e1, M. et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J. Kidney Dis. 47, 406\u2013411 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201054_CR75","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/13813450802033818","volume":"114","author":"K Kankov\u00e1","year":"2008","unstructured":"Kankov\u00e1, K. et al. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch. Physiol. Biochem. 114, 111\u2013119 (2008).","journal-title":"Arch. Physiol. Biochem."},{"key":"BFnrneph201054_CR76","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1210\/jc.2009-1067","volume":"94","author":"KH Gaens","year":"2009","unstructured":"Gaens, K. H. et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J. Clin. Endocrinol. Metab. 94, 5174\u20135180 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph201054_CR77","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1681\/ASN.2005010062","volume":"16","author":"JM Forbes","year":"2005","unstructured":"Forbes, J. M. et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16, 2363\u20132372 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201054_CR78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11154-008-9100-6","volume":"9","author":"FC Brosius 3rd.","year":"2008","unstructured":"Brosius, F. C. 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 9, 245\u2013254 (2008).","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"3","key":"BFnrneph201054_CR79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10753-009-9167-6","volume":"33","author":"Kum Hyun Han","year":"2009","unstructured":"Han, K. H., Han, S. Y., Kim, H. S., Kang, Y. S. & Cha, D. R. Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy. Inflammation doi:10.1007\/s10753-009-9167-6.","journal-title":"Inflammation"},{"key":"BFnrneph201054_CR80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1440-1681.2009.05292.x","volume":"37","author":"LC Matavelli","year":"2010","unstructured":"Matavelli, L. C., Huang, J. & Siragy, H. M. (Pro)renin receptor contributes to diabetic nephropathy through enhancing renal inflammation. Clin. Exp. Pharmacol. Physiol. 37, 277\u2013282 (2010).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"BFnrneph201054_CR81","doi-asserted-by":"publisher","first-page":"F1229","DOI":"10.1152\/ajprenal.00074.2009","volume":"297","author":"D Min","year":"2009","unstructured":"Min, D. et al. Mesangial cell derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 297, F1229\u2013F1237 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201054_CR82","doi-asserted-by":"publisher","first-page":"F1622","DOI":"10.1152\/ajprenal.00078.2009","volume":"297","author":"J Wu","year":"2009","unstructured":"Wu, J., Mei, C., Vlassara, H., Striker, G. E. & Zheng, F. Oxidative stress induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells. Am. J. Physiol. Renal Physiol. 297, F1622\u2013F1631 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201054_CR83","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1189\/jlb.71.3.433","volume":"71","author":"KS Collison","year":"2002","unstructured":"Collison, K. S. et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J. Leukoc. Biol. 71, 433\u2013444 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrneph201054_CR84","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1172\/JCI116442","volume":"91","author":"AM Schmidt","year":"1993","unstructured":"Schmidt, A. M. et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 91, 2155\u20132168 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201054_CR85","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.4049\/jimmunol.173.2.1399","volume":"173","author":"Y Chen","year":"2004","unstructured":"Chen, Y. et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J. Immunol. 173, 1399\u20131405 (2004).","journal-title":"J. Immunol."},{"key":"BFnrneph201054_CR86","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20040934","volume":"201","author":"G Cataldegirmen","year":"2005","unstructured":"Cataldegirmen, G. et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J. Exp. Med. 201, 473\u2013484 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrneph201054_CR87","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbrc.2009.02.040","volume":"381","author":"Q Chen","year":"2009","unstructured":"Chen, Q., Dong, L., Wang, L., Kang, L. & Xu, B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem. Biophys. Res. Commun. 381, 192\u2013197 (2009).","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.54","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:35:52Z","timestamp":1685572552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2010.54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,27]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFnrneph201054"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2010.54","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,27]]}}}